Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : CYWC628
Therapeutic Area : Podiatry
Study Phase : Preclinical
Recipient : Charles River Laboratories, Inc
Deal Size : Undisclosed
Deal Type : Collaboration
FibroBiologics and Charles River Partner for Fibroblast Cell-Based Therapies
Details : The collaboration aims to develop and manufacture FibroBiologics’ therapeutic master cell bank, working cell bank, and fibroblast-based spheroids product, CYWC628, for diabetic foot ulcer (DFU).
Brand Name : CYWC628
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
October 18, 2024
Lead Product(s) : CYWC628
Therapeutic Area : Podiatry
Highest Development Status : Preclinical
Recipient : Charles River Laboratories, Inc
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?